about
Cost-Effectiveness of Disease-Modifying Therapies in Multiple SclerosisExpression of activity-dependent neuroprotective protein in the immune system: possible functions and relevance to multiple sclerosisMutations in FRMD7, a newly identified member of the FERM family, cause X-linked idiopathic congenital nystagmus.Paediatric Multiple Sclerosis: Update on Diagnostic Criteria, Imaging, Histopathology and Treatment ChoicesThe human gene for mannan-binding lectin-associated serine protease-2 (MASP-2), the effector component of the lectin route of complement activation, is part of a tightly linked gene cluster on chromosome 1p36.2-3Coordinate based meta-analysis of functional neuroimaging data using activation likelihood estimation; full width half max and group comparisonsSubjective discomfort in children receiving 3 T MRI and experienced adults' perspective on children's tolerability of 7 T: a cross-sectional questionnaire surveyCoordinate based meta-analysis of functional neuroimaging data; false discovery control and diagnostics.Histogram analysis of quantitative T1 and MT maps from ultrahigh field MRI in clinically isolated syndrome and relapsing-remitting multiple sclerosis.Spinal cord imaging in multiple sclerosis.Multiple sclerosis findings in the spinal cord.Are current disease-modifying therapeutics in multiple sclerosis justified on the basis of studies in experimental autoimmune encephalomyelitis?Tobacco smoking and excess mortality in multiple sclerosis: a cohort study.Serum uric acid levels in optic neuritis.Extra-hippocampal subcortical limbic involvement predicts episodic recall performance in multiple sclerosis.Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up studyCannabinoids and experimental models of multiple sclerosis.Helicobacter pylori infection reduces disease severity in an experimental model of multiple sclerosisMortality in multiple sclerosis: meta-analysis of standardised mortality ratios.Multiple sclerosis course and clinical outcomes in patients with comorbid asthma: a survey study.Glucocorticoids increase CD4CD25 cell percentage and Foxp3 expression in patients with multiple sclerosis.Discrepant effects of human interferon-gamma on clinical and immunological disease parameters in a novel marmoset model for multiple sclerosis.Corpus callosum changes following shunting for hydrocephalus: case report and review of the literature.Effects of pro-inflammatory cytokines on cannabinoid CB1 and CB2 receptors in immune cellsCognitive Rehabilitation for Attention and Memory in people with Multiple Sclerosis: study protocol for a randomised controlled trial (CRAMMS).Tumor necrosis factor alpha and lymphotoxin alpha are not required for induction of acute experimental autoimmune encephalomyelitis.Role of oral teriflunomide in the management of multiple sclerosis.Tobacco smoking and disability progression in multiple sclerosis: United Kingdom cohort study.Modulation of regulatory T cells in health and disease: role of toll-like receptors.Platelet activating factor/platelet activating factor receptor pathway as a potential therapeutic target in autoimmune diseases.Novel therapeutic approaches to autoimmune demyelinating disorders.Fatigue in multiple sclerosis - a brief review.Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis.Diagnosis and management of Neuro-Behçet's disease: international consensus recommendationsPharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis.The essential role of T cells in multiple sclerosis: a reappraisal.Advances in the treatment of relapsing-remitting multiple sclerosis.Diagnostic modalities in multiple sclerosis: perspectives in children.Helminth Therapy for MS.What role does tobacco smoking play in multiple sclerosis disability and mortality? A review of the evidence.
P50
Q22252598-D88F382D-B1D1-4F2A-8F53-F8BDFEA9C119Q24603606-B332323C-B1F6-4E6A-AF53-55149205DEEBQ24651919-1C06E113-D814-4481-A913-3A2573CF2C71Q26748229-1CDCD96F-B13C-4B23-9D0B-4770973D193CQ28203787-5815D681-8298-49D7-82E3-5D300591F051Q30366849-EC74A7E8-5E1F-44D5-B721-59902BB05023Q30428038-53FFE0CE-C003-4440-AB84-79F5CD2C62C4Q30660078-DE43CF18-A22D-4A65-9F26-AA99DDCE4090Q30992091-4E1E5F82-501F-486F-8264-EB65B40784FBQ31027973-1B52F6AD-C966-440F-BF0D-459ED4204621Q31128783-DA35C6FB-BED9-45D7-9FBA-47A75E80E4B6Q34135135-7542F984-0B26-432F-945B-BA50FDD2A977Q34237659-50AA36BA-398A-4E27-9D9E-87029254A76AQ34329742-06EB5EC7-3550-4253-B9B5-CD4A71C004B4Q34440853-8D1DCB98-3698-46DE-A907-688B8F401924Q34565669-F64FE707-C4DD-4213-BE16-04FFF224DA3AQ34611995-BF3FEEF1-15F8-49A8-97F2-B8CE43470929Q35082342-28F617D6-9EC5-48E2-A439-D137C649C68BQ35621002-499A3A16-C7D1-47AA-B545-BEBFE3AEB63DQ35640291-C4E02CB0-D37C-43C7-A977-C6095A279FCCQ35742927-FA31B612-6F11-4FB4-A5B1-12E2043DD0B5Q35759597-B4BE066A-FE34-4ED6-9D93-6078BC08A869Q36122737-7C8F27D2-25F6-457F-95FC-CB4D083B372CQ36347677-A65CA7FB-D25C-43D5-8CA9-3B9314D3B859Q36354299-597F9CB6-1D19-4D04-80AC-F9A9ED1AD3EBQ36377351-3256FD53-E8F4-4C35-8AB0-A19E81F55AA3Q36803649-E88296D5-ED17-436D-A1A7-A182C69CD6F7Q36953860-516EB088-AD39-4B0C-9876-7B389AAECDACQ37521119-CC9ACF9F-0AF5-4910-901D-158D5BF19934Q37550960-83FAA4E4-7933-4603-9371-1DA32954F206Q37921832-E7833383-4748-437A-9201-9F29E31BB9DEQ38039273-B0E0149B-9AA6-4BA9-B0DB-12A003EB8E91Q38041231-2083CF4A-7D90-4F1A-AFAC-AA7E062D1C80Q38173702-D2477638-E4A1-44C3-9695-3B6AF96B6A1AQ38192006-113512D2-AE70-45BB-A9D3-503555D92078Q38204623-1FCFFBA0-2B33-4EB2-B6CE-969D7A2F834DQ38204624-498A97FE-0FF2-4CE6-8328-400E151DF203Q38204625-C8878273-105B-4A12-9529-D1B6375D03BEQ38282742-A5634849-F19E-4F5F-A54F-9400367DC13AQ38364823-EABB606F-473E-464E-84C4-1BF2664C7DDE
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Cris Constantinescu
@ast
Cris Constantinescu
@en
Cris Constantinescu
@es
Cris Constantinescu
@nl
Cris Constantinescu
@sl
type
label
Cris Constantinescu
@ast
Cris Constantinescu
@en
Cris Constantinescu
@es
Cris Constantinescu
@nl
Cris Constantinescu
@sl
prefLabel
Cris Constantinescu
@ast
Cris Constantinescu
@en
Cris Constantinescu
@es
Cris Constantinescu
@nl
Cris Constantinescu
@sl
P106
P1153
35420038300
P31
P496
0000-0003-2066-7585